DECRYPTION – Growing evidence suggests that beyond the treatment of diabetes and obesity, the therapeutic effects of GLP-1 agonists such as Ozempic or Wegowy could extend to many other pathologies.
Ozempic, Wegowy… These drugs, initially intended for diabetic patients, have recently made the headlines for their effectiveness against severe obesity and the excesses of influencers using them to easily lose a few pounds. But these glucagon-like peptide-1 (or anti-GLP-1) agonists could have more than one trick up their sleeve. Because work is accumulating and, with it, new promises that scientists themselves did not expect: reducing kidney and liver problems, addictive disorders, even slowing down cognitive decline in neurodegenerative diseases… Will the indication of these drugs soon be extended to many pathologies other than diabetes and obesity?
Diabetic patients smoke and drink less
There are dozens of studies. Among the most unexpected results, GLP-1 agonists could help treat addictions by suppressing irrepressible urges (“craving”)…
This article is reserved for subscribers. You have 87% left to discover.
Do you want to read more?
Unlock all items immediately. No commitment.
Already subscribed? Log in
France
Health
